Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01308242 · ClinicalTrials.gov registry record · Early Phase 1
Effects of a Non-Calcium Based Phosphate Binder on FGF23 Levels in Chronic Kidney Disease
A Early Phase 1 study, sponsored by Milton S. Hershey Medical Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 40
- Enrollment target
NCT01308242 is a Early Phase 1 study that has completed, run by Milton S. Hershey Medical Center. The registered enrollment target is 40 participants.
The verdict
NCT01308242, a Early Phase 1 study, has completed, sponsored by Milton S. Hershey Medical Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
Fibroblast Growth Factor 23 (FGF23) is a molecule that has been implicated in the homeostasis of phosphorus. Elevated FGF23 levels are well-documented in patients with Chronic Kidney Disease (CKD) and are inversely correlated with Glomerular Filtration Rate (GFR). FGF23 levels are also predictive of progression of CKD and predict mortality in CKD. Although studies in normal individuals suggest that phosphorus intake is related to FGF23 levels, the effect of dietary and pharmacologic phosphate restriction on FGF23 levels in patients with CKD has never been reported. Our objectives are to determine if phosphate reduction through the use of non-calcium based phosphate binder will decrease serum FGF23 levels. The investigators will also be investigating associations of elevation in FGF 23 levels with commonly encountered co-morbidities in CKD patients such as Coronary Artery Disease, Diabetes Mellitus, and Hypertension.
Interventions
- DRUG Sevelamer Carbonate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2011-03 |
| Est. Completion | 2014-02-27 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01308242
The ClinicalTrials.gov registry entry for NCT01308242 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sevelamer Carbonate is the first listed.
NCT01308242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01308242 about?
NCT01308242 is a clinical study titled "Effects of a Non-Calcium Based Phosphate Binder on FGF23 Levels in Chronic Kidney Disease". Fibroblast Growth Factor 23 (FGF23) is a molecule that has been implicated in the homeostasis of phosphorus. Elevated FGF23 levels are well-documented in patients with Chronic Kidney Disease (CKD) and are inversely correlated with Glomerular Filtration Rate (GFR). FGF23 levels are also predictive of...
What is the current status of trial NCT01308242?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 40 participants. The study started on 2011-03. Estimated completion is 2014-02-27.
What interventions are being tested in trial NCT01308242?
The interventions under investigation include: Sevelamer Carbonate (DRUG).
Who is sponsoring clinical trial NCT01308242?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.